3-D Matrix Ltd (JP:7777)

:7777

7777

3-D Matrix

RESEARCH TOOLSreports

3-D Matrix (7777) Price & Analysis

2 Followers

7777 Stock Chart & Stats

¥348.00

-¥2.00(-1.17%)

At close: Jan 08 4:00 PM EST

¥348.00

-¥2.00(-1.17%)

Day’s Range― - ―

52-Week Range¥102.00 - ¥793.00

Previous CloseN/A

Volume2.54M

Average Volume (3M)4.78M

Market Cap

¥56.36B

Enterprise Value¥51.49B

Total Cash (Recent Filing)¥1.49B

Total Debt (Recent Filing)¥2.33B

Price to Earnings (P/E)20.6

Beta1.58

Next Earnings

Jun 11, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)7.99

Shares Outstanding124,965,080

10 Day Avg. Volume2,399,770

30 Day Avg. Volume4,782,760

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)5.64

Price to Sales (P/S)1.80

P/FCF Ratio-7.24

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Gross MarginA sustained ~64% gross margin indicates strong product-level profitability and pricing power in the biomaterials portfolio. Durable margins provide a cushion to fund R&D and commercialization, improving long-term scalability even while operating profitability is pursued.

Proprietary Technology And Diversified RevenueOwning self-assembling peptide IP plus multiple monetization paths (product sales, licensing, institutional partnerships) creates a structural moat. Diversified revenue sources reduce single-channel risk and support recurring and milestone-based income as clinical adoption grows.

Free Cash Flow Covering Net LossesFCF roughly covering accounting losses shows the business can generate cash despite reported net losses. This provides a tangible runway advantage, reducing immediate refinancing pressure and enabling continued investment in trials and commercialization in the medium term.

Bears Say

High LeverageA 1.33 debt/equity ratio signals material reliance on debt capital, increasing interest and covenant risk. High leverage constrains strategic flexibility, raises refinancing vulnerability in tighter markets, and can crowd out R&D or commercialization spend if servicing costs rise.

Negative Operating Cash FlowPersistently negative operating cash flow implies core operations do not yet fund working capital and growth. That forces dependence on external financing or asset/liability management, increasing execution risk for clinical programs and commercial rollouts over the coming quarters.

Persistent Net Losses And Negative ROEOngoing net losses and negative return on equity reflect inability to convert revenue into shareholder returns. Over time this can erode investor support, hamper capital raising on favorable terms, and limit reinvestment capacity needed to scale commercialization.

3-D Matrix News

3-D Matrix and Harvard Achieve Breakthrough in Cardiac Regenerative Therapy

The latest announcement is out from 3-D Matrix ( ($JP:7777) ). 3-D Matrix, Ltd. has achieved a significant...

6M ago

7777 FAQ

What was 3-D Matrix Ltd’s price range in the past 12 months?

3-D Matrix Ltd lowest stock price was ¥102.00 and its highest was ¥793.00 in the past 12 months.

What is 3-D Matrix Ltd’s market cap?

3-D Matrix Ltd’s market cap is ¥56.36B.

When is 3-D Matrix Ltd’s upcoming earnings report date?

3-D Matrix Ltd’s upcoming earnings report date is Jun 11, 2026 which is in 69 days.

How were 3-D Matrix Ltd’s earnings last quarter?

3-D Matrix Ltd released its earnings results on Dec 11, 2025. The company reported ¥7.99 earnings per share for the quarter, beating the consensus estimate of N/A by ¥7.99.

Is 3-D Matrix Ltd overvalued?

According to Wall Street analysts 3-D Matrix Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does 3-D Matrix Ltd pay dividends?

3-D Matrix Ltd does not currently pay dividends.

What is 3-D Matrix Ltd’s EPS estimate?

3-D Matrix Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does 3-D Matrix Ltd have?

3-D Matrix Ltd has 124,965,080 shares outstanding.

What happened to 3-D Matrix Ltd’s price movement after its last earnings report?

3-D Matrix Ltd reported an EPS of ¥7.99 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -5.075%.

Which hedge fund is a major shareholder of 3-D Matrix Ltd?

Currently, no hedge funds are holding shares in JP:7777

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

3-D Matrix Ltd

3-D Matrix, Ltd. develops self-assembling peptide technology. It offers PuraMatrix, a self-assembling peptide hydrogel for use in the fields of regenerative medicine, cell therapy, drug delivery technology, and surgical treatment. The company was founded in 2004 and is based in Tokyo, Japan.